Literature DB >> 16635432

Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Martin Stangel1, Corinna Trebst.   

Abstract

Spontaneous remyelination and repair mechanisms in multiple sclerosis are mostly insufficient and contribute to clinical disability. Treatments improving these processes are not yet available but basic research in animal models has led to the proposal of several repair strategies. These include enhancement of the naturally occurring mechanisms, remyelination due to a change of the immune response, and transfer of myelinating cells. Despite the encouraging experimental findings and the constantly increasing knowledge of the molecular mechanisms of remyelination and remyelination failure, there remain many questions before this knowledge can be successfully translated into clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16635432     DOI: 10.1007/s11910-006-0010-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  67 in total

1.  Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells.

Authors:  D Nguyen; M Stangel
Journal:  Brain Res Dev Brain Res       Date:  2001-05-31

2.  CNS integrins switch growth factor signalling to promote target-dependent survival.

Authors:  Holly Colognato; Wia Baron; Virginia Avellana-Adalid; Jõao B Relvas; Anne Baron-Van Evercooren; Elisabeth Georges-Labouesse; Charles ffrench-Constant
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

3.  Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage.

Authors:  Dale Fortin; Eran Rom; Haijun Sun; Avner Yayon; Rashmi Bansal
Journal:  J Neurosci       Date:  2005-08-10       Impact factor: 6.167

4.  Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation.

Authors:  Stephen A Back; Therese M F Tuohy; Hanqin Chen; Nicholas Wallingford; Andrew Craig; Jaime Struve; Ning Ling Luo; Fatima Banine; Ying Liu; Ansi Chang; Bruce D Trapp; Bruce F Bebo; Mahendra S Rao; Larry S Sherman
Journal:  Nat Med       Date:  2005-08-07       Impact factor: 53.440

5.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

6.  Pattern of remyelination in the CNS.

Authors:  W F Blakemore
Journal:  Nature       Date:  1974-06-07       Impact factor: 49.962

7.  A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

8.  Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.

Authors:  Costanza Savino; Rosetta Pedotti; Fulvio Baggi; Federica Ubiali; Barbara Gallo; Sara Nava; Paolo Bigini; Sara Barbera; Elena Fumagalli; Tiziana Mennini; Annamaria Vezzani; Massimo Rizzi; Thomas Coleman; Anthony Cerami; Michael Brines; Pietro Ghezzi; Roberto Bianchi
Journal:  J Neuroimmunol       Date:  2005-12-07       Impact factor: 3.478

9.  Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.

Authors:  M R Kotter; A Setzu; F J Sim; N Van Rooijen; R J Franklin
Journal:  Glia       Date:  2001-09       Impact factor: 7.452

Review 10.  Remyelinating strategies for the treatment of multiple sclerosis.

Authors:  Martin Stangel; Hans-Peter Hartung
Journal:  Prog Neurobiol       Date:  2002-12       Impact factor: 11.685

View more
  3 in total

1.  Mice lacking Gpr37 exhibit decreased expression of the myelin-associated glycoprotein MAG and increased susceptibility to demyelination.

Authors:  Brilee M Smith; Michelle M Giddens; Jessica Neil; Sharon Owino; TrangKimberly T Nguyen; Duc Duong; Fengqiao Li; Randy A Hall
Journal:  Neuroscience       Date:  2017-06-20       Impact factor: 3.590

Review 2.  Magnetic nanoparticles for oligodendrocyte precursor cell transplantation therapies: progress and challenges.

Authors:  Stuart I Jenkins; Humphrey H P Yiu; Matthew J Rosseinsky; Divya M Chari
Journal:  Mol Cell Ther       Date:  2014-07-28

Review 3.  Nonmuscle myosin-2: mix and match.

Authors:  Sarah M Heissler; Dietmar J Manstein
Journal:  Cell Mol Life Sci       Date:  2012-05-08       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.